In today’s briefing:
- Telix Pharmaceuticals (TLX AU): Stepping Ahead with First Product Approved in the U.S.
Telix Pharmaceuticals (TLX AU): Stepping Ahead with First Product Approved in the U.S.
- Last month, Telix Pharmaceuticals (TLX AU) received FDA approval for its first cancer imaging product, Illuccix. Commercial launch of Illuccix will be the major milestone for the company in 2022.
- EU approval for Illucix is expected in March. Illuccix has multi-billion-dollar global market opportunity, driven by rising incidence of prostate cancer, increasing clinical adoption, and geography expansion.
- The company has a rich pipeline targeting seven indications, having high unmet medical needs. Telix is expected to file for kidney cancer imaging product, TLX250-CDx in early 2022.
Before it’s here, it’s on Smartkarma
